

RECEIVED

JAN 12 2004

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elizabeth M. Denholm, Elizabeth Cauchon, and Paul J. Silver

Serial No.: 09/727,873

Art Unit: 1651

Filed: December 1, 2000

Examiner: M. Meller

For: *ATTENUATION OF FIBROBLAST PROLIFERATION*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including five (5) pages of Form PTO-1449 and a copy of each document cited therein.

Enclosed is a check for \$180.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 C.F.R. §1.97(c). It is believed that no additional fees are required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,695,752	12-09-1997	Rosen et al.	424/94.61

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 98/46258 A2	10-22-1998	Beth Isreal Deaconess Medical Center, Inc.	PCT
WO 99/484778 A1	09-30-1999	Insight Strategy & Marketing Ltd.	PCT
WO 95/13091 A1	05-18-1995	International Technology Management Associates, Ltd.	PCT
WO 96/01894 A1	01-25-1996	Ibex Technologies Research & Development, Inc.	PCT

Publications

BENSADOUN, et al. "Proteoglycan deposition in pulmonary fibrosis," *Amer. J. Respir. Crit. Care Med.* 154:1819-1828 (1996).

DENHOLM, "Inhibition of fibroblast by Chondroitinase AC(CAC) and Chondroitinase B(CB)," *FASEB J* 12(5):A948 1998).

DENHOLM, et al., "Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate," *European Journal of Pharmacology* 400:145-153 (2000).

DENHOLM & PHAN, "The effects of bleomycin on alveolar macrophage growth factor secretion," *Amer. J. Pathol.* 134:355-363 (1989).

DONATI, et al., "Treatment of hypertrophic and keloid cicatrices with thiomucase," *Minerva Chirurgica* 30(6):326-33 AN-Medline 76196588 (1975).

FANNON & NUGENT, "Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate," *J. Biol. Chem.* 271:17949-17956 (1996).

FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," *J. Am. Coll. Cardiol.* 17:758-769 (1991).

JACKSON, et. al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," *Physiol. Rev.* 71:481-530 (1991).

KELLER, et al., "Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chlorate," *Biochem.* 28:8100-8107 (1989).

KJELLEN & LINDAHL, "Proteoglycans: structures and interactions," *Ann. Rev. Biochem.* 60:443-475 (1991).

- LINHARDT, et al., "Polysaccharide lyases," *Appl. Biochem. Biotech.* 12:135-175 (1986).
- LINN, et al. "Isolation and characterization of two chondroitin lyases from *Bacteroides thetaiotaomicron*," *J. Bacteriol.* 156:859-866 (1983).
- LIU & CONNOLLY, "Isolation and characterization of two chondroitin lyases from *Bacteroides thetaiotaomicron*," *Sem. Cutaneous Med. and Surg.* 17:3-11 (1998).
- LYON, et al., "Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate," *J. Biol. Chem.* 273:271-278 (1998).
- MAEDA, et al., "6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)," *J. Biol. Chem.* 271:21446-21452 (1996).
- MIAO, et al., "Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor," *J. Cell. Biochem.* 57:173-184 (1995).
- MICHELACCI, et. al., "Isolation and characterization of an induced chondroitinase ABC from *Flavobacterium heparinum*," *Biochim. Biophys. Acta.* 923:291-201 (1987).
- MILEV, et al., "The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity," *J. Biol. Chem.* 273:21439-21442 (1998).
- PENC & GALLO, "Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function," *J. Biol. Chem.* 273:28116-28121 (1998).
- PHAN & KUNKEL, "Lung cytokine production in bleomycin-induced pulmonary fibrosis," *Exper. Lung Res.* 18:29-43 (1992).
- RICHARDSON & HATTON, "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," *Exp. Mol. Pathol.* 58:77-95 (1993).
- SATO, et. al., "Submit structure of Chondroitinase ABC from *Proteus vulgaris*," *Agric. Biol. Chem.* 50:1057-1059 (1986).
- SCHMIDT, et al., "The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues," *J. Biol. Chem.* 267:19242-19247 (1992).
- SCHWARTZ, "Regulation of chondroitin sulfate synthesis. Effect of beta-xylosides on synthesis of chondroitin sulfate proteoglycan, chondroitin sulfate chains, and core protein," *J. Biol. Chem.* 252:6316-6321 (1977).

SEGARINI, et al., "Binding of transforming growth factor-beta to cell surface proteins varies with cell type," *Molecular Endocrinol.* 3:261-272 (1989).

SUNDBERG, et al., "Development and progression of psoriasiform dermatitis and systemic lesions in the flaky skin (fsn) mouse mutant," *Pathobiology* 65:271-286 (1997).

TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," *J. Biol. Chem.* 268(27):20419-20432 (1993).

TAO, et. al., "Elevated expression of proteoglycans in proliferating vascular smooth muscle cells," *Atherosclerosis* 135:171-179 (1997).

VARANI, et al., "Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion," *Amer. J. Pathol.* 145:561-573 (1994).

VLODAVSKY, et al., "Control of cell proliferation by heparan sulfate and heparin-binding growth factors," *Thrombosis Haemostasis* 74:534-540 (1995).

YAMAGATA, et al., "Purification and properties of bacterial chondroitinases and chondrosulfatases," *J. Biol. Chem.* 243:1523-1535 (1968).

YAYON, et al., "Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor," *Cell* 64:841-848 (1991).

YEO, et al. Alterations in proteoglycan synthesis common to healing wounds and tumors," *Amer. J. Pathol.* 138:1437-1450 (1991).

ZHANG, et. al., "In situ hybridization analysis of rat lung alpha 1(I) and alpha 2(I) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection," *Lab. Invest.* 70: 192-202 (1994).

U.S.S.N.: 09/727,873
Filed: December 1, 2000
INFORMATION DISCLOSURE STATEMENT



RECEIVED

JAN 12 2004

TECH CENTER 1600/2900

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: February 8, 2002

Kimberly L. Adams

ATL1 #507007 v1

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

09/727,873

Filing Date

December 1, 2000

First Named Inventor

Elizabeth M. Denholm

Group Art Unit

1651

Examiner Name

M. Meller

Attorney Docket Number

IT 105

Sheet

2

of

5

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BENSADOUN, et al. "Proteoglycan deposition in pulmonary fibrosis," <i>Amer. J. Respir. Crit. Care Med.</i> 154:1819-1828 (1996).	
		DENHOLM & PHAN, "The effects of bleomycin on alveolar macrophage growth factor secretion," <i>Amer. J. Pathol.</i> 134:355-363 (1989).	
		DENHOLM, "Inhibition of fibroblast by Chondrotinase AC(CAC) and Chondrotinase B(CB)," <i>FASEB J</i> 12(5):A948 1998).	
		DENHOLM, et al., "Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate," <i>European Journal of Pharmacology</i> 400:145-153 (2000).	
		DONATI, et al., "Treatment of hypertrophic and keloid cicatrices with thiomucase," <i>Minerva Chirurgica</i> 30(6):326-33 AN-Medline 76196588 (1975).	
		FANNON & NUGENT, "Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate," <i>J. Biol. Chem.</i> 271:17949-17956 (1996).	
		FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," <i>J. Am. Coll. Cardiol.</i> 17:758-769 (1991).	
		JACKSON, et al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," <i>Physiol. Rev.</i> 71:481-530 (1991).	
		KELLER, et al., "Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chlorate," <i>Biochem.</i> 28:8100-8107 (1989).	
		KJELLEN & LINDAHL, "Proteoglycans: structures and interactions," <i>Ann. Rev. Biochem.</i> 60:443-475 (1991).	

Examiner's
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 <p>Use as many sheets as necessary)</p>		Application Number	09/727,873
		Filing Date	December 1, 2000
		First Named Inventor	Elizabeth M. Denholm
		Group Art Unit	1651
		Examiner Name	M. Meller
		Attorney Docket Number	IT 105
Sheet	3	of	5

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LINHARDT, et al., "Polysaccharide lyases," <i>Appl. Biochem. Biotech.</i> 12:135-175 (1986).	
		LINN, et al. "Isolation and characterization of two chondroitin lyases from <i>Bacteroides thetaiotaomicron</i> ," <i>J. Bacteriol.</i> 156:859-866 (1983).	
		LIU & CONNOLLY, "Isolation and characterization of two chondroitin lyases from <i>Bacteroides thetaiotaomicron</i> ," <i>Sem. Cutaneous Med. and Surg.</i> 17:3-11 (1998).	
		LYON, et al., "Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate," <i>J. Biol. Chem.</i> 273:271-278 (1998).	
		MAEDA, et al., "6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM)," <i>J. Biol. Chem.</i> 271:21446-21452 (1996).	
		MIAO, et al., "Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor," <i>J. Cell. Biochem.</i> 57:173-184 (1995).	
		MICHELACCI, et. al., "Isolation and characterization of an induced chondroitinase ABC from <i>Flavobacterium heparinum</i> ," <i>Biochim. Biophys. Acta.</i> 923:291-201 (1987).	
		MILEV, et al., "The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity," <i>J. Biol. Chem.</i> 273:21439-21442 (1998).	
		PENC & GALLO, "Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function," <i>J. Biol. Chem.</i> 273:28116-28121 (1998).	
		PHAN & KUNKEL, "Lung cytokine production in bleomycin-induced pulmonary fibrosis," <i>Exper. Lung Res.</i> 18:29-43 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

RECEIVED

JAN 12 2004

Please type a plus sign (+) inside this box →



TECH CENTER 1600/2900

 PTO/SB/08A (10-96)
 Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/727,873
		Filing Date	December 1, 2000
		First Named Inventor	Elizabeth M. Denholm
		Group Art Unit	1651
		Examiner Name	M. Meller
		Attorney Docket Number	IT 105
Sheet	4	of	5

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		RICHARDSON & HATTON, "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," <i>Exp. Mol. Pathol.</i> 58:77-95 (1993).	
		SATO, et. al., "Submit structure of Chondroitinase ABC from <i>Proteus vulgaris</i> ," <i>Agric. Biol. Chem.</i> 50:1057-1059 (1986).	
		SCHMIDT, et al., "The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues," <i>J. Biol. Chem.</i> 267:19242-19247 (1992).	
		SCHWARTZ, "Regulation of chondroitin sulfate synthesis. Effect of beta-xylosides on synthesis of chondroitin sulfate proteoglycan, chondroitin sulfate chains, and core protein," <i>J. Biol. Chem.</i> 252:6316-6321 (1977).	
		SEGARINI, et al., "Binding of transforming growth factor-beta to cell surface proteins varies with cell type," <i>Molecular Endocrinol.</i> 3:261-272 (1989).	
		SUNDBERG, et al., "Development and progression of psoriasiform dermatitis and systemic lesions in the flaky skin (fsn) mouse mutant," <i>Pathobiology</i> 65:271-286 (1997).	
		TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," <i>J. Biol. Chem.</i> 268(27):20419-20432 (1993).	
		TAO, et. al., "Elevated expression of proteoglycans in proliferating vascular smooth muscle cells," <i>Atherosclerosis</i> 135:171-179 (1997).	
		VARANI, et al., "Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion," <i>Amer. J. Pathol.</i> 145:561-573 (1994).	
		VLODAVSKY, et al., "Control of cell proliferation by heparan sulfate and heparin-binding growth factors," <i>Thrombosis Haemostasis</i> 74:534-540 (1995).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JAN 12 2004

Please type a plus sign (+) inside this box →



TECH CENTER 1600/2900

 PTO/SB/08A (10-96)
 Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/727,873		
		Filing Date	December 1, 2000		
		First Named Inventor	Elizabeth M. Denholm		
		Group Art Unit	1651		
		Examiner Name	M. Meller		
Sheet	5	of	5	Attorney Docket Number	IT 105

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		YAMAGATA, et al., "Purification and properties of bacterial chondroitinases and chondrosulfatases," <i>J. Biol. Chem.</i> 243:1523-1535 (1968).	
		YAYON, et al., "Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor," <i>Cell</i> 64:841-848 (1991).	
		YEO, et al. Alterations in proteoglycan synthesis common to healing wounds and tumors," <i>Amer. J. Pathol.</i> 138:1437-1450 (1991).	
		ZHANG, et. al., "In situ hybridization analysis of rat lung alpha 1(I) and alpha 2(I) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection," <i>Lab. Invest.</i> 70: 192-202 (1994).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.